Literature DB >> 20923314

Neurocysticercosis.

Jack Moskowitz1, Geoffrey Mendelsohn.   

Abstract

Neurocysticercosis is a significant public health issue within the United States. Although cysticercosis was once thought to have been eradicated in the United States, the number of documented cases is rising and immigrants from endemic areas are at the highest risk for acquiring and developing this disease. The clinical presentation of neurocysticercosis is variable and vague neurologic symptoms or sudden unexplained death in individuals with risk factors may be the only available information warranting a consideration of neurocysticercosis. Radiologic and laboratory findings can help guide medical and surgical interventions, while histologic confirmation establishes a more definitive diagnosis. Encysted larvae can be found throughout the central nervous system and undergo progressive stages of decay. Degenerating vesicles elicit an inflammatory response, involving surrounding structures, and cause the major clinical symptomatology.

Entities:  

Mesh:

Year:  2010        PMID: 20923314     DOI: 10.5858/2008-0756-RS.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Cranial hypertrophic pachymeningitis secondary to neurocysticercosis.

Authors:  Thiago Cardoso Vale; Helena Duani; Daniela Lino Macedo; Paulo Pereira Christo
Journal:  Neurol Sci       Date:  2012-03-09       Impact factor: 3.307

Review 2.  Clinical manifestations, diagnosis, and treatment of neurocysticercosis.

Authors:  Julio Sotelo
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

3.  The surgical removal of a live tapeworm with an interesting pathologic finding most likely representing the migration path: a case report of cerebral sparganosis.

Authors:  Peng Wang; Xueying Su; Qing Mao; Yanhui Liu
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

4.  Chronic administration of cryptolepine nanoparticle formulation alleviates seizures in a neurocysticercosis model.

Authors:  Priscilla Kolibea Mante; Nana Ofori Adomako; Paulina Antwi; Nana Kofi Kusi-Boadum
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.